AZNAstraZenecaRunning, no new patients
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
Biliary Tract Cancer
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Oct 2025, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 3
- Patients
- 142 (final count)
- Started
- Aug 16, 2023
- Main results expected
- Oct 2, 2025
- Fully finished
- Sep 17, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with Grade 3 or 4 possibly related adverse event (PRAE)
Measured over: Within 6 months after the initiation of Investigational Medicinal Product (IMP)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-10-02, no fading
Raw record changes
- none yet
Trial ID NCT05771480 · record last updated 2026-07-29 · checked 2026-11-09 15:47 UTC